Home Halogens 8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile

8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile

CAS No.:
915365-57-0
Catalog Number:
AG00GU2L
Molecular Formula:
C27H27Cl2FN8
Molecular Weight:
553.4613
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
2mg
98%
1 week
United States
$290
- +
5mg
98%
1 week
United States
$440
- +
10mg
98%
1 week
United States
$673
- +
25mg
98%
1 week
United States
$1323
- +
50mg
98%
1 week
United States
$2307
- +
100mg
98%
1 week
United States
$3723
- +
Product Description
Catalog Number:
AG00GU2L
Chemical Name:
8-Chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[[[1-[2-(hexahydro-1H-azepin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]amino]-3-Quinolinecarbonitrile
CAS Number:
915365-57-0
Molecular Formula:
C27H27Cl2FN8
Molecular Weight:
553.4613
MDL Number:
MFCD13184699
IUPAC Name:
6-[[1-[2-(azepan-1-yl)ethyl]triazol-4-yl]methylamino]-8-chloro-4-(3-chloro-4-fluoroanilino)quinoline-3-carbonitrile
InChI:
InChI=1S/C27H27Cl2FN8/c28-23-12-19(5-6-25(23)30)34-26-18(14-31)15-33-27-22(26)11-20(13-24(27)29)32-16-21-17-38(36-35-21)10-9-37-7-3-1-2-4-8-37/h5-6,11-13,15,17,32H,1-4,7-10,16H2,(H,33,34)
InChI Key:
ZWFKJFUFYPOTKL-UHFFFAOYSA-N
SMILES:
N#Cc1cnc2c(c1Nc1ccc(c(c1)Cl)F)cc(cc2Cl)NCc1nnn(c1)CCN1CCCCCC1
Properties
Complexity:
792  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
552.172g/mol
Formal Charge:
0
Heavy Atom Count:
38  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
553.467g/mol
Monoisotopic Mass:
552.172g/mol
Rotatable Bond Count:
8  
Topological Polar Surface Area:
94.7A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
5.8  
Literature
Title Journal
Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorganic & medicinal chemistry letters 20090701
Properties